Analyst Confidence Rises for Sangamo Ahead of Financial Report

Sangamo Therapeutics reports FY 2025 results March 30. Analysts eye EPS of $0.01, $40.25M revenue, and updates on Fabry disease therapy ST-920's regulatory path.

Investor attention is turning to Sangamo Therapeutics as the company prepares to release its full-year 2025 financial results. The report, scheduled for Monday, March 30, after the U.S. market close, is anticipated to provide critical insights into the biotech firm's financial health and its strategy for funding ongoing clinical trials.

Financial Forecasts and Pipeline Momentum

Market consensus estimates project Sangamo will report earnings per share of $0.01 on revenue of approximately $40.25 million for the fourth quarter and full year 2025. These figures are viewed as a key indicator of the company's operational stability heading into the new fiscal period.

Beyond the numbers, significant developments in the clinical pipeline are fueling optimism. The company has initiated a rolling Biologics License Application (BLA) submission for its lead candidate, ST-920, a potential therapy for Fabry disease. Furthermore, Sangamo recently presented data from its STAAR study at the WORLDSymposium 2026, underscoring continued progress in its research programs.

Financing and Revised Price Targets

To support these clinical initiatives and general operations, Sangamo secured $25 million in capital through a financing round completed in February. While this move resulted in dilution for existing shareholders, it bolstered the company's near-term liquidity.

Despite the dilutive effect of this capital raise, market observers have grown notably more bullish. Analysts have revised their expectations upward, lifting the average price target for Sangamo shares to $3.89. This represents a substantial premium to the current trading price of around $0.35. The equity has already responded positively to these adjustments, posting moderate gains in after-hours trading following the announcements.

Key Focus for the Upcoming Call

Management is expected to host a conference call on March 30 to discuss the financial results. A primary focus for investors will be any additional details provided regarding the anticipated timeline for the ST-920 regulatory approval process. Clarification on this front, along with confirmation of revenue guidance, is likely to be a decisive factor for the stock's near-term valuation.